Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Journal of Clinical Medicine
|
June 26, 2025
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients
Fabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, et al.
Clinical and Experimental Rheumatology
|
July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry
Maria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Rheumatology and Therapy
|
September 17, 2020
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment
Luca Navarini, Francesco Caso, Luisa Costa, et al.
The Journal of Rheumatology
|
December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation
Marco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Scientific Reports
|
May 7, 2022
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis
Luca Navarini, Damiano Currado, Annalisa Marino, et al.
Clinical and Experimental Rheumatology
|
April 21, 2023
The negative impact of pain catastrophising on disease activity: analyses of data derived from patient-reported outcomes in psoriatic arthritis and axial spondyloarthritis
Damiano Currado, Alice Biaggi, Andrea Pilato, et al.
Scientific Reports
|
October 30, 2025
Pain catastrophizing and its domains significantly impact rheumatoid arthritis disease activity
Damiano Currado, Lyubomyra Kun, Francesca Saracino, et al.
Arthritis Research & Therapy
|
September 18, 2024
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study
Damiano Currado, Francesca Saracino, Piero Ruscitti, et al.
Clinical and Experimental Rheumatology
|
August 31, 2023
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs
Laura Scagnellato, Antonio Collesei, Andrea Doria, et al.
Therapeutic Advances in Musculoskeletal Disease
|
February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
Giuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Journal of Clinical Medicine
|
June 26, 2025
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients
Fabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, et al.
Clinical and Experimental Rheumatology
|
July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry
Maria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Rheumatology and Therapy
|
September 17, 2020
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment
Luca Navarini, Francesco Caso, Luisa Costa, et al.
The Journal of Rheumatology
|
December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation
Marco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Scientific Reports
|
May 7, 2022
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis
Luca Navarini, Damiano Currado, Annalisa Marino, et al.
Clinical and Experimental Rheumatology
|
April 21, 2023
The negative impact of pain catastrophising on disease activity: analyses of data derived from patient-reported outcomes in psoriatic arthritis and axial spondyloarthritis
Damiano Currado, Alice Biaggi, Andrea Pilato, et al.
Scientific Reports
|
October 30, 2025
Pain catastrophizing and its domains significantly impact rheumatoid arthritis disease activity
Damiano Currado, Lyubomyra Kun, Francesca Saracino, et al.
Arthritis Research & Therapy
|
September 18, 2024
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study
Damiano Currado, Francesca Saracino, Piero Ruscitti, et al.
Clinical and Experimental Rheumatology
|
August 31, 2023
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs
Laura Scagnellato, Antonio Collesei, Andrea Doria, et al.
Therapeutic Advances in Musculoskeletal Disease
|
February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
Giuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Page
of 9